Literature DB >> 9245608

p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents.

K Wehrly1, B Chesebro.   

Abstract

Antigen capture enzyme-linked immunosorbent assay (ELISA) for quantitation of the p24 gag protein of human immunodeficiency virus type-1 (HIV-1) is currently the most common method used to demonstrate virus replication both in vivo and in vitro. The present paper describes an ELISA employing readily available inexpensive reagents and gives detailed suggestions for optimizing the variables for specific purposes. The assay is as sensitive as commercial kits (25 pg/ml) and has a linear dose response over a wide range of p24 concentrations (25-1000 pg/ml). For these reasons, as well as its low cost, this assay has proven useful in a variety of research applications. This assay also has been found to be effective in detecting the gag protein of human immunodeficiency virus type-2 and simian immunodeficiency virus.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9245608     DOI: 10.1006/meth.1997.0481

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  96 in total

1.  Sam68 enhances the cytoplasmic utilization of intron-containing RNA and is functionally regulated by the nuclear kinase Sik/BRK.

Authors:  John H Coyle; Brian W Guzik; Yeou-Cherng Bor; Li Jin; Lucia Eisner-Smerage; Stephen J Taylor; David Rekosh; Marie-Louise Hammarskjöld
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

2.  APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis.

Authors:  Holly A Sadler; Mark D Stenglein; Reuben S Harris; Louis M Mansky
Journal:  J Virol       Date:  2010-05-12       Impact factor: 5.103

3.  Single-nucleotide changes in the HIV Rev-response element mediate resistance to compounds that inhibit Rev function.

Authors:  Deidra Shuck-Lee; Hua Chang; Emily A Sloan; Marie-Louise Hammarskjold; David Rekosh
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

4.  Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells.

Authors:  Brett M Forshey; Jiong Shi; Christopher Aiken
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Analysis of human cell heterokaryons demonstrates that target cell restriction of cyclosporine-resistant human immunodeficiency virus type 1 mutants is genetically dominant.

Authors:  Chisu Song; Christopher Aiken
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

6.  Nef does not affect the efficiency of human immunodeficiency virus type 1 fusion with target cells.

Authors:  Minoru Tobiume; Janet E Lineberger; Christopher A Lundquist; Michael D Miller; Christopher Aiken
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.

Authors:  H J de Haard; B Kazemier; M J Koolen; L J Nijholt; R H Meloen; B van Gemen; H R Hoogenboom; J W Arends
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

8.  The neuroinvasiveness of a murine retrovirus is influenced by a dileucine-containing sequence in the cytoplasmic tail of glycosylated Gag.

Authors:  R Fujisawa; F J McAtee; K Wehrly; J L Portis
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Stability of HIV Frameshift Site RNA Correlates with Frameshift Efficiency and Decreased Virus Infectivity.

Authors:  Pablo Garcia-Miranda; Jordan T Becker; Bayleigh E Benner; Alexander Blume; Nathan M Sherer; Samuel E Butcher
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

10.  Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.

Authors:  Vasundhara Varthakavi; Rita M Smith; Stephan P Bour; Klaus Strebel; Paul Spearman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.